NEW YORK (GenomeWeb News) – Austrian firm Anagnostics Bioanalysis today announced a deal granting Italian company Cell.ENG the exclusive right to sell Anagnostics' KRAS mutation test in Italy.
Terms of the deal were not disclosed.
The Anagnostics KRAS Test is for detecting mutations in the KRAS gene. Such mutations have been shown to limit the efficacy of cancer therapeutics that block the epidermal growth factor receptor. The test is based on a technology called hybcell, which Anagnostics called "a unique further development of the microarray technology."
"[T]he microarray is integrated into a rotating cylinder filled with the [patient] sample," it said, adding the technology enables the measurement of "many test parameters" simultaneously.
Markus Jacquemar, CEO of Anagnostics, said in a statement, "Up until now, the real time polymerase chain reaction was considered to be state-of-the-art for companion diagnostics in the area of mutation analysis. Our technology now not only enables faster and unambiguous results, but also higher sensitivity and simpler operation."
The company is working with Diatech Pharmacogenetics on developing combined tests for the KRAS, BRAF, and EGFR genes to be sold across Europe. Anagnostics has secured funding from Technet Equity NO Technologiebeteiligungs-Invest, it said.
The company, founded in 2006, develops systems and tests for research and clinical multiplex diagnostics.